341 related articles for article (PubMed ID: 33099890)
1. COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?
Saeedi-Boroujeni A; Mahmoudian-Sani MR; Bahadoram M; Alghasi A
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):37-45. PubMed ID: 33099890
[TBL] [Abstract][Full Text] [Related]
2. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.
Saeedi-Boroujeni A; Mahmoudian-Sani MR; Nashibi R; Houshmandfar S; Tahmaseby Gandomkari S; Khodadadi A
Immunopharmacol Immunotoxicol; 2021 Jun; 43(3):247-258. PubMed ID: 34015982
[TBL] [Abstract][Full Text] [Related]
3. Curcumin ameliorates monosodium urate-induced gouty arthritis through Nod-like receptor 3 inflammasome mediation via inhibiting nuclear factor-kappa B signaling.
Li X; Xu DQ; Sun DY; Zhang T; He X; Xiao DM
J Cell Biochem; 2019 Apr; 120(4):6718-6728. PubMed ID: 30592318
[TBL] [Abstract][Full Text] [Related]
4. [Role of inflammasome NLRP3 in the pathophysiology of viral infections: A focus on SARS-CoV-2 infection].
Chemarin M; Dufies O; Mazet A; Mellan E; Coudereau R; Py BF; Boyer L; Venet F
Med Sci (Paris); 2022; 38(6-7):545-552. PubMed ID: 35766852
[TBL] [Abstract][Full Text] [Related]
5. Curcumin Suppresses IL-1β Secretion and Prevents Inflammation through Inhibition of the NLRP3 Inflammasome.
Yin H; Guo Q; Li X; Tang T; Li C; Wang H; Sun Y; Feng Q; Ma C; Gao C; Yi F; Peng J
J Immunol; 2018 Apr; 200(8):2835-2846. PubMed ID: 29549176
[TBL] [Abstract][Full Text] [Related]
6. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.
Bonaventura A; Vecchié A; Dagna L; Tangianu F; Abbate A; Dentali F
Inflamm Res; 2022 Mar; 71(3):293-307. PubMed ID: 35113170
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of the NLRP3 inflammasome suppresses immune overactivation and alleviates COVID-19 like pathology in mice.
Zeng J; Xie X; Feng XL; Xu L; Han JB; Yu D; Zou QC; Liu Q; Li X; Ma G; Li MH; Yao YG
EBioMedicine; 2022 Jan; 75():103803. PubMed ID: 34979342
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the NLRP3 inflammasome by Sars-CoV-2 Envelope protein.
Yalcinkaya M; Liu W; Islam MN; Kotini AG; Gusarova GA; Fidler TP; Papapetrou EP; Bhattacharya J; Wang N; Tall AR
Sci Rep; 2021 Dec; 11(1):24432. PubMed ID: 34952919
[TBL] [Abstract][Full Text] [Related]
9. Curcumin alleviates DSS-induced colitis via inhibiting NLRP3 inflammsome activation and IL-1β production.
Gong Z; Zhao S; Zhou J; Yan J; Wang L; Du X; Li H; Chen Y; Cai W; Wu J
Mol Immunol; 2018 Dec; 104():11-19. PubMed ID: 30396035
[TBL] [Abstract][Full Text] [Related]
10. The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies.
Zhao N; Di B; Xu LL
Cytokine Growth Factor Rev; 2021 Oct; 61():2-15. PubMed ID: 34183243
[TBL] [Abstract][Full Text] [Related]
11. Curcumin mitigates aflatoxin B1-induced liver injury via regulating the NLRP3 inflammasome and Nrf2 signaling pathway.
Wang Y; Liu F; Liu M; Zhou X; Wang M; Cao K; Jin S; Shan A; Feng X
Food Chem Toxicol; 2022 Mar; 161():112823. PubMed ID: 35063475
[TBL] [Abstract][Full Text] [Related]
12. Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19.
Yong YY; Zhang L; Hu YJ; Wu JM; Yan L; Pan YR; Tang Y; Yu L; Law BY; Yu CL; Zhou J; Li M; Qin DL; Zhou XG; Wu AG
Clin Immunol; 2022 Nov; 244():109093. PubMed ID: 35944881
[TBL] [Abstract][Full Text] [Related]
13. [Progress in the relationship between NLRP3 inflammasome and lung injury in COVID-19].
Ren Z; Che P; Li Z; Mo M; Zhang S; Zhang Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Sep; 37(9):844-850. PubMed ID: 34533131
[TBL] [Abstract][Full Text] [Related]
14. Curcumin suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock.
Gong Z; Zhou J; Li H; Gao Y; Xu C; Zhao S; Chen Y; Cai W; Wu J
Mol Nutr Food Res; 2015 Nov; 59(11):2132-42. PubMed ID: 26250869
[TBL] [Abstract][Full Text] [Related]
15. The purinergic receptor P2X7 and the NLRP3 inflammasome are druggable host factors required for SARS-CoV-2 infection.
Lécuyer D; Nardacci R; Tannous D; Gutierrez-Mateyron E; Deva Nathan A; Subra F; Di Primio C; Quaranta P; Petit V; Richetta C; Mostefa-Kara A; Del Nonno F; Falasca L; Marlin R; Maisonnasse P; Delahousse J; Pascaud J; Deprez E; Naigeon M; Chaput N; Paci A; Saada V; Ghez D; Mariette X; Costa M; Pistello M; Allouch A; Delelis O; Piacentini M; Le Grand R; Perfettini JL
Front Immunol; 2023; 14():1270081. PubMed ID: 37920468
[TBL] [Abstract][Full Text] [Related]
16. Arglabin could target inflammasome-induced ARDS and cytokine storm associated with COVID-19.
Manayi A; Nabavi SM; Khayatkashani M; Habtemariam S; Khayat Kashani HR
Mol Biol Rep; 2021 Dec; 48(12):8221-8225. PubMed ID: 34655016
[TBL] [Abstract][Full Text] [Related]
17. Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1β/neutrophil extracellular traps feedback loop.
Yaqinuddin A; Kashir J
Med Hypotheses; 2020 Oct; 143():109906. PubMed ID: 32505910
[TBL] [Abstract][Full Text] [Related]
18. Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.
Root-Bernstein R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672738
[TBL] [Abstract][Full Text] [Related]
19. The hidden role of NLRP3 inflammasome in obesity-related COVID-19 exacerbations: Lessons for drug repurposing.
Bertocchi I; Foglietta F; Collotta D; Eva C; Brancaleone V; Thiemermann C; Collino M
Br J Pharmacol; 2020 Nov; 177(21):4921-4930. PubMed ID: 32776354
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of IL-6 and NLRP3 inflammasome as potential therapeutic targets to combat COVID-19: Role of lncRNAs in cytokine storm modulation.
Paniri A; Akhavan-Niaki H
Life Sci; 2020 Sep; 257():118114. PubMed ID: 32693241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
